The first step in determining whether your patient is suitable for MitraClip® therapy is to perform a transthoracic echocardiogram (TTE) of the mitral valve to assess anatomical suitability.
Optimal imaging can help determine MR etiology, mechanism, and severity for the most accurate assessment of your patients' eligibility
Download the quick reference guide, which includes all the recommended TTE images above and a standardized screening checklist to help ensure the Heart Team has everything they need to make the most informed decision about MitraClip® eligibility.DOWNLOAD >
The guideline supports frequent monitoring and performance of routine TTEs. TTEs are recommended in the initial evaluation of patients with known or suspected DMR and should be performed with any change in symptoms or physical examination findings.1
Asymptomatic patients with severe DMR and normal LV function should have TTEs performed every 6-12 months, and those with dilating LV even more frequently.1
MitraClip® NT Clip Delivery System
INDICATION FOR USE
The MitraClip® NT Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
Prior to use, please reference the Instructions for Use at www.abbottvascular.com/ifu for more information on indications, contraindications, warnings, precautions, and adverse events.